What did the IOM Committee conclude? What were its recommendations?
Until the safety and efficacy of testosterone therapy is older men is established, the Committee said that—outside of clinical trials—supplements of this hormone are only appropriate for indications approved by the FDA (the primary indication is hypogonadism in men who make little or no testosterone). Testosterone therapy, the Committee concluded, is inappropriate for widespread, generalized use to prevent possible age-related diseases or for enhancing strength or mood in otherwise healthy older men.
